LLY Eli Lilly and Company

Price (delayed)

$163.87

Market cap

$156.73B

P/E Ratio

27

Dividend/share

$2.77

EPS

$6.07

Enterprise value

$172.26B

Business Summary

Sector: Healthcare
Industry: Drug Manufacturers - General
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Highlights

The equity has increased by 24% year-on-year and by 18% since the previous quarter
The company's gross profit rose by 8% YoY and by 3.9% QoQ
The P/E is 67% above the last 4 quarters average of 16.2 but 38% below the 5-year quarterly average of 43.7
The net income has contracted by 34% from the previous quarter and by 12% YoY
The EPS has decreased by 32% QoQ and by 3.8% YoY

Key stats

Shares outstanding
956.45M
Market cap
$156.73B
Enterprise value
$172.26B
EBIT
$6.21B
EBITDA
$7.36B
Price to earnings (P/E)
27
Price to book (P/B)
50.9
Price to sales (P/S)
6.45
EV/EBIT
27.72
EV/EBITDA
23.39
Net debt/EBITDA
2.11
EV/Sales
7.46
EBITDA margin
31.9%
Gross margin
79.2%
Net margin
24%
Operating margin
26.9%
Return on assets
14.1%
Return on equity
186.8%
Return on invested capital
20.1%
Return on capital employed
21.8%
Return on sales
26.9%
Debt to equity
5.6
Free cash flow
$3.82B
Free cash flow per share
$4.21
Book value per share
$3.22
Revenue per share
$25.42
TBVPS
$32.54
Current ratio
1.11
Quick ratio
0.64
Working capital
$1.38B
Dividend yield
1.69%
DPS
$2.77
Payout ratio
45.6%

LLY stock price

Financial performance

LLY's operating income has surged by 104% year-on-year and by 18% since the previous quarter
ELI LILLY & Co's operating margin has soared by 91% YoY and by 14% from the previous quarter
ELI LILLY & Co's net margin has decreased by 36% from the previous quarter and by 17% YoY
The net income has contracted by 34% from the previous quarter and by 12% YoY

Valuation

Price to earnings (P/E)
Current price to earnings (P/E):
27
The P/E is 67% above the last 4 quarters average of 16.2 but 38% below the 5-year quarterly average of 43.7
The EPS has decreased by 32% QoQ and by 3.8% YoY
Price to book (P/B)
Current price to book (P/B):
50.9
LLY's P/B is 26% above its last 4 quarters average of 40.5
The equity has increased by 24% year-on-year and by 18% since the previous quarter
Price to sales (P/S)
Current price to sales (P/S):
6.45
The stock's price to sales (P/S) is 40% more than its 5-year quarterly average of 4.6 and 27% more than its last 4 quarters average of 5.1
ELI LILLY & Co's revenue has increased by 7% YoY and by 3.4% from the previous quarter

Efficiency

The company's return on equity has surged by 176% YoY but it fell by 37% QoQ
The ROA has contracted by 35% from the previous quarter and by 4.7% YoY
The ROS has decreased by 33% QoQ and by 14% YoY
The ROIC has contracted by 31% from the previous quarter and by 11% YoY

Dividends

DPS
$2.77
Dividend yield
1.69%
Payout ratio
45.6%

Recent dividends

Financial health

Assets vs liabilities
LLY's total assets is 8% greater than its total liabilities
LLY's total assets is up by 8% year-on-year and by 4.6% since the previous quarter
ELI LILLY & Co's total liabilities has increased by 7% YoY and by 3.6% from the previous quarter
Debt vs equity
The equity has increased by 24% year-on-year and by 18% since the previous quarter
The company's debt to equity fell by 16% YoY and by 4.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.